散发性Alzheimer病患者脑源性神经营养因子基因C270T多态性的研究

目的探讨中国汉族人群散发性Alzheimer病(SAD)患者脑源性神经营养因子(BDNF)基因C270T多态性与AD发病的关系。方法采用聚合酶链反应限制性片段长度多态性(PCR-RFLP)技术,检测55例SAD患者和80名年龄、性别匹配的健康人(正常对照组)BDNF基因C270T多态性,比较两组基因型分布和等位基因频率。结果正常对照组BDNFC270T基因型及等位基因频率分布符合Hardy-Weinberg定律(χ2=0.167,P=0.682),SAD组基因型[C/C型52例(94.5%),C/T型3例(5.5%)]及等位基因频率(C97.27%,T2.73%)分布与正常对照组[C/C型74例(92.5%),C/T型6例(7.5%);C96.25%,T3.75%]比较差异无统计学意义。结论中国汉族人群BDNF基因C270T多态性与SAD的发病无明显关系。     

脑源性神经营养因子基因多态性与精神分裂症的关联研究

目的:探讨脑源性神经营养因子(BDNF)基因多态性与精神分裂症的关联性.方法:以111例精神分裂症发作期患者与362例正常对照为研究对象,通过TagMan探针单核苷酸多态性(SNP)基因分型技术对BDNF基因及基因上游10 kb区域的标签SNPs rs6265和rs11030101进行基因分型,比较各组间基因型、等位基...     

精神分裂症脑源性神经营养因子C270T基因多态性研究

目的 探讨脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)基因C270T多态性与精神分裂症的相关性.方法 用聚合酶链反应技术检测224例精神分裂症和220例正常人的BDNF基因C270T基因型和等位基因,以阳性与阴性症状量表评定患者的临床症状,比较C270T基因型和等位基因分布频率差异及其与精神分裂症临床症状的相关性.结果 患者组的C/T基因型分布频率显著高于对照组(27.7％ vs.6.8％),P＜ 0.01;T等位基因分布频率显著高于对照组(14.7％ vs.3.2％)P＜0.001;BDNF基因C270T的基因型C/C、C/T、T/T分布频率和等位基因C、T的分布频率,阳性组与阴性组比较差异均无统计学意义(均P＞0.05).结论 BDNF基因C270T多态性与精神分裂症相关,但与临床症状不相关.     

脑源性神经营养因子与抑郁症

神经营养因子是神经元网络形成和可塑性的重要调节因子,以脑源性神经营养因子(BDNF)最受关注。抗抑郁治疗通过提高BDNF表达来促进神经元可塑性,从而取得疗效。本文从临床前研究、临床研究和基因多态性等方面对BDNF与抑郁症作一综述。     

抑郁症患者脑源性神经营养因子Va166Met多态性与血清浓度的关系

目的 探讨脑源性神经营养因子(BDNF)基因Va166Met多态性与抑郁症之间的关系以及Va166Met多态性是否影响血清BDNF浓度.方法 对76例未经药物治疗的抑郁症患者和50例正常人,用限制性片段长度多态性方法分析Va166Met多态性,采用酶联吸附反应方法对血清BDNF浓度进行检测.结果 (1)抑郁症患者血清BDNF浓度(24.7±12.7)ng/ml显著低于正常对照组(36.6±16.4)pg/ml,差异有统计学意义(P＜0.01);(2)抑郁症组和对照组之间的Va166Met多态性位点的等位基因频率和基因型分布差异无统计学意义(P＞0.05);(3)在押郁症组和对照组,Val/Met+Met/Met基因型组与Val/Val基因型相比,血清BDNF浓度差异无统计学意义(P＞0.05).结论 抑郁症患者存在较低的血清BDNF水平,BDNF基因Val66Met多态性与抑郁症之间无相关性,Va166Met多态性对血清BDNF水平浓度无明显影响.     

抑郁症患者脑源性神经营养因子Val66Met多态性与血清浓度的关系

目的探讨脑源性神经营养因子（BDNF）基因Val66Met多态性与抑郁症之同的关系以及Val66Met多态性是否影响血清BDNF浓度。方法对76例未经药物治疗的抑郁症患者和50例正常人,用限制性片段长度多态性方法分析Val66Met多态性,采用酶联吸附反应方法对血清BDNF浓度进行检测。结果（1）抑郁症患者血清BDNF浓度（24．7±12．7）ng／m1显著低于正常对照组（36．6±16．4）pg／m｜,差异有统计学意义（P〈0．01）;（2）抑郁症组和对照组之间的Val66Met多态性位点的等位基因频率和基因型分布差异无统计学意义（P〉0．05）;（3）在抑郁症组和对照组,Val／Met＋Met／Met基因型组与Val／Val基因型相比,血清BDNF浓度差异无统计学意义（P〉0．05）。结论抑郁症患者存在较低的血清BDNF水平,BDNF基因Val66Met多态性与抑郁症之间无相关性,Val66Met多态性对血清BDNF水平浓度无明显影响。     

脑源性神经营养因子基因C270T多态性与儿童精神分裂症的关系

目的 探讨脑源性神经营养因子(BDNF)基因C270T多态性与儿童精神分裂症的关系.方法 采用病例对照研究,用聚合酶链反应-限制性片段长度多态性方法,分析204例儿童精神分裂症患者和210名健康对照的BDNF基因C270T多态性;进行阳性与阴性症状量表(PANSS)评定,用Andremson阳性与阴性精神分裂症分型标准将患者分为阴性症状为主型(阴性组)和阳性症状为主型(阳性组).结果 ①患者组和对照组间BDNF基因C270T多态性的基因型频率差异有统计学意义(χ2=24.56,P<0.01),前者的C/T型和T/T型频率高于后者;患者组等位基因T频率显著高于对照组(χ2=24.04,P<0.01);②阴性组、阳性组、对照组3组间基因型及等位基因分布的差异均有统计学义(χ2=37.93,P<0.01;χ2=38.90,P<0.01);两两比较显示,阴性组、阳组分别与对照组比较,基因型及等位基因分布差异均有统计学义(P<0.001).③不同基因型患者组之间PANSS各因子分和总分差异均无统计学意义(P>0.05).结论 BDNF C270T多态性与儿童精神分裂症有关,但与具体临床表现之间无明显的关系.     

脑源性神经营养因子与精神分裂症

脑源性神经营养因子BDNF在精神分裂症发病中的作用得到了越来越广泛的关注。目前研究发现,BDNF与精神分裂症发病机制假说、分裂症动物模型的建立及分裂症治疗均存在相关性。通过综合评价该领域近年来的实验结果,对BDNF与精神分裂症的关系作一综述。     

脑源性神经营养因子基因单体型与散发性Alzheimer病的关系

目的分析汉族人群中脑源性神经营养因子(BDNF)基因G196A、C270T、G11757C和G712A单核苷酸多态性(SNPs)和单体型频率与散发性Alzheimer病(sAD)的关系。方法采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,检测106例sAD患者和110名健康对照者BDNFG196A、C270T、G11757C和G712A基因型和等位基因频率,采用SHEsis软件进行连锁不平衡及单体型分析。结果sAD组及健康对照组C270T位点T等位基因频率分别为0.9%及4.5%,G712A位点GG基因型频率分别为95.4%、91.8%,A等位基因频率分别为0.5%及4.5%;两组比较差异有统计学意义(均P<0.05)。单体型分析显示,sAD组和健康对照组GTGA频率分别为0.5%和3.2%,差异有统计学意义(P<0.05)。结论BDNF基因多态性可能与中国汉族人群sAD发病有关。     

脑源性神经营养因子基因多态性与强迫症的关联研究

目的:探讨脑源性神经营养因子(BDNF)基因与强迫症(OCD)的关联性。方法:190例OCD患者和309个健康对照为研究对象,通过聚合酶链式反应与限制性片段长度多态性(PCR-RFLP)基因分型技术对BDNF基因标签单核苷酸多态性(SNP)位点rs6265进行基因分型。以耶鲁-布朗强迫量表(Y-BOCS)评定OCD患者的病情。结果:OCD组和对照组之间rs6265位点的基因型和等位基因频率分布差异无统计学意义(P>0.05)。在起病年龄和性别方面基因型和等位基因频率分布差异也无统计学意义(P>0.05)。结论:BDNF基因rs6265多态性与OCD可能没有关联。     

Evidence for Association between the Brain-Derived Neurotrophic Factor Gene and Panic Disorder: A Novel Haplotype Analysis

Objective

Panic disorder (PD) is a common psychiatric disorder with a complex etiology, and several studies have suggested that it has a genetic component. Brain-derived neurotrophic factor (BDNF) is the most abundant of the neurotrophins in the brain and is recognized for its important role in the survival, differentiation and growth of neurons. Several lines of research have suggested possible associations between the BDNF gene and PD. In this study, we investigated the BDNF 196G/A (rs6265), 11757G/C (rs16917204), and 270C/T (rs56164415) single nucleotide polymorphisms (SNPs) in order to determine an association with PD. We also identified the genetic sequence associations with PD via haplotype analysis.

Methods

Participants in this study included 136 PD patients and 263 healthy controls. Male and female subjects were analyzed separately. The genotype and allele frequencies of the PD patients and controls were analyzed using χ² statistics. Frequencies and haplotype reconstructions were calculated using the SNP analyzer 2.0.

Results

We found no significant statistical differences in the genotype distributions or allele frequencies of the three tested polymorphisms between the PD and control groups. In addition, no differences were found between PD patients and the controls in either male or female subgroups. However, we found that, the frequency of the G-C haplotype for 196G/A and 11757G/C was significantly higher in PD patients than in the controls.

Conclusion

Our result suggest that patients with the G-C haplotype for 196G/A and 11757G/C may be more susceptible to the development of PD. Further studies are needed to replicate the associations that we observed.     

Decreased Serum Brain-Derived Neurotrophic Factor Levels in Elderly Korean with Dementia

Objective

The primary purpose of this study was to investigate the differences in the serum brain-derived neurotrophic factor (BDNF) level between elderly Korean people over 65 years with and without dementia.

Methods

171 individuals over 65 years were enrolled in this study. Screening for cognitive impairments was carried out using the Mini-Mental Status Examination-Korean version (MMSE-KC). One hundred thirty-two subjects scored below 1.5 standard deviations (SD) of the mean MMSE-KC score, and these were evaluated using the Consortium to Establish a Registry for Alzheimer''s Disease, Korean version (CERAD-K) and the Geriatric Depression Scale (GDS). The Clinical Dementia Rating Scale (CDRS) and the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnostic criteria were used for further evaluation. Subjects with a CDRS score of 1 or higher were classified as having Alzheimer''s disease (AD), and subjects with a CDRS score of 0.5 were classified as having a mild cognitive impairment (MCI). Subjects with a CDRS score of 0 were classified as having aging-associated cognitive decline (AACD). Serum BDNF levels were analyzed using the enzyme-linked immunosorbent assay (ELISA) method.

Results

The serum BDNF levels were significantly lower in the subjects with MCI and AD compared with the healthy controls (p<0.01). A significant correlation was found between the total MMSE-KC score and serum BDNF level (r=0.295; p<0.01). However, no significant correlation was observed between the severity of MMSE-KC and the total GDS score. A significant difference was found in the total score of GDS between the AACD group and subjects with AD (p<0.05).

Conclusion

This study suggested that BDNF might be involved in the pathophysiology of cognitive decline in elderly people.     

高血压对慢性脑缺血大鼠海马和大脑皮质的脑源性神经营养因子表达的影响

目的 探讨高血压对慢性脑缺血大鼠海马及大脑皮质部位脑源性神经营养因子（Brain-derivedneurotrophic factor,BDNF）表达的影响。方法 使用正常血压的WKY大鼠以及有高血压的SHR大鼠制作双侧总颈动脉永久阻塞的慢性脑缺血模型。应用原位杂交及免疫组织化学染色观察BDNF在缺血后第1～4周的变化,H&E染色比较缺血后第4周脑梗死范围的大小。结果 慢性脑缺血后,在SHR大鼠海马CA1和大脑皮质,BDNF的mRNA及免疫染色密度在缺血后第1~4周皆有显著的减少（P <0.05）,蛋白质印迹（Western-blot）实验也呈现了相同的结果。而WKY大鼠,只在缺血后第1周有短暂的减少（P <0.05）。在第4周,HE染色显示SHR大鼠比WKY大鼠有较大范围的脑组织受损（[ 12.40±4.26）% vs（0.41±0.17）%,P =0.026]。结论 在慢性脑缺血的情况下,长期的高血压会加重脑损伤,并且影响BDNF的mRNA及蛋白质的表达,尤其在缺血耐受性低的海马CA1及大脑皮质部位。     

散发性阿尔茨海默病患者血清脑源性神经营养因子的测定及临床意义

目的探讨散发性阿尔茨海默病(sporadic Alzhei mer disease,SAD)患者血清脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)变化及其临床意义。方法选择2004-11—2005-10作者医院门诊及住院SAD患者43例,其中轻度痴呆18例,中度痴呆19例,重度痴呆6例。对照组35例为同期体检者。采用酶联免疫吸附法(ELISA)测定外周血清BDNF水平。结果SAD组和对照组间性别(χ2=0.0042,P=0.9483)、年龄(t=0.38,P=0.7023)及血清BDNF水平(t=0.60,P=0.5528)差异均无统计学意义,轻、中、重度SAD组及对照组间血清BDNF水平比较亦无统计学意义(F=0.89,P=0.4526)。结论SAD患者外周血清BDNF水平无明显变化,血清BDNF水平不能作为SAD诊断的标志物,也不能反映痴呆的严重程度。     

Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism Is a Risk Factor for Attention-Deficit Hyperactivity Disorder in a Turkish Sample

ObjectiveAttention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that negatively affects different areas of life. We aimed to evaluate the associations between the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) and ADHD and to assess the effect of the BDNF polymorphism on the neurocognitive profile and clinical symptomatology in ADHD.MethodsTwo hundred one ADHD cases and 99 typically developing subjects (TD) between the ages of 8 and 15 years were involved in the study. All subjects were evaluated using a complete neuropsychological battery, Child Behavior Checklist, the Teacher''s Report Form (TRF) and the DSM-IV Disruptive Behavior Disorders Rating Scale-teacher and parent forms.ResultsThe GG genotype was significantly more frequent in the patients with ADHD than in the TD controls, and the GG genotype was also significantly more frequent in the ADHD-combined (ADHD-C) subtype patients than in the TDs. However, there were no significant associations of the BDNF polymorphism with the ADHD subtypes or neurocognitive profiles of the patients. The teacher-assessed hyperactivity and inattention symptom count and the total score were higher, and the appropriately behaving subtest score of the TRF was lower in the GG genotypes than in the GA and AA (i.e., the A-containing) genotypes.ConclusionWe found a positive association between the BDNF gene Val66Met polymorphism and ADHD, and this association was observed specifically in the ADHD-C subtype and not the ADHD-predominantly inattentive subtype. Our findings support that the Val66Met polymorphism of BDNF gene might be involved in the pathogenesis of ADHD. Furthermore Val66Met polymorphism of BDNF gene may be more closely associated with hyperactivity rather than inattention.     

Endogenous Control of Hippocampal Epileptogenesis: A Molecular Cascade Involving Brain-Derived Neurotrophic Factor and Neuropeptide Y

Summary: Purpose : Seizures increase the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. Because this neurotrophin exerts modulatory effects on hippocampal neuronal excitability, it may play an important role in epileptogenesis initiated in this structure. Moreover BDNF is known to regulate the expression of neuropeptide Y (NPY), which displays modulatory properties on seizure activity. This suggests that the effects of BDNF on epileptogenesis may be mediated by NPY.
Methods : Adult male rats received a 7-day chronic intrahippocampal infusion of BDNF, BDNF antisense oligodeoxy-nucleotides, NPY, or anti-NPY immunoglobulin G during kindling of the hippocampus. The long-term regulation of NPY expression by BDNF was also studied by immunohistochemistry and radioimmunoassay.
Results : BDNF applied during the first week of hippocampal stimulation significantly delayed the progression of kindling, an effect that outlasted the end of the infusion by at least 7 days. Conversely, infusion of BDNF antisense oligodeoxynucleotides to reduce the expression of endogenous BDNF in the hippocampus aggravated the electroencephalographic expression of seizures. Chronic infusion of BDNF increased the expression of NPY in the hippocampus, with a time course similar to that of the protective effect of the neurotrophin on kindling. Finally, chronic infusion of NPY in the hippocampus delayed the progression of hippocampal kindling, whereas anti-NPY antibodies had an aggravating effect.
Conclusions : Our results suggest that the seizure-induced increase in BDNF expression in the hippocampus may constitute an endogenous protective mechanism able to counteract hippocampal epileptogenesis. This protective effect appears to be mediated at least in part through the regulation of NPY expression.     

Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs

Objective

It is important to predict a response to an antidepressant in early time after starting the antidepressant. We previously reported that serum brain-derived neurotrophic factor (BDNF) levels in responders to treatment with antidepressants were increased, whereas, those in nonresponders were not. Therefore, we hypothesized that the changes in serum levels of BDNF from baseline (T0) to 4 weeks (T4) after treatment with selective serotonin reuptake inhibitors (SSRIs) predict the response to the treatment at 8 weeks (T8) in depressed patients. To confirm the hypothesis, we measured serum BDNF at T0, T4, and T8 during the treatment with SSRIs (paroxetine, sertraline, and fluvoxamine).

Methods

One hundred fifty patients (M/F; 51/99, age; 50.4±15.1 years) met major depressive disorder (MDD) using by DSM-IV-TR enrolled in the present study. We measured serum BDNF concentrations at T0, T4, and T8 in patients with MDD treated with SSRIs.

Results

The changes in serum BDNF, age, sex, dose of SSRIs, and HAMD-17 score did not predict the response to SSRIs at T8.

Conclusion

These results suggest that the changes in serum BDNF levels from T0 to T4 could not predict the subsequent responses to SSRIs at T8.     

Brain-Derived Neurotrophic Factor Polymorphism Influences Response to Single-Pulse Transcranial Magnetic Stimulation at Rest

ObjectivesThe ability of noninvasive brain stimulation to modulate corticospinal excitability and plasticity is influenced by genetic predilections such as the coding for brain-derived neurotrophic factor (BDNF). Otherwise healthy individuals presenting with BDNF Val66Met (Val/Met) polymorphism are less susceptible to changes in excitability in response to repetitive transcranial magnetic stimulation (TMS) and paired associative stimulation paradigms, reflecting reduced neuroplasticity, compared to Val homozygotes (Val/Val). In the current study, we investigated whether BDNF polymorphism influences “baseline” excitability under TMS conditions that are not repetitive or plasticity-inducing. Cross-sectional BDNF levels could predict TMS response more generally because of the ongoing plasticity processes.Materials and MethodsForty-five healthy individuals (23 females; age: 25.3 ± 7.0 years) participated in the study, comprising two groups. Motor evoked potentials (MEP) were collected using single-pulse TMS paradigms at fixed stimulation intensities at 110% of the resting motor threshold in one group, and individually-derived intensities based on MEP sizes of 1 mV in the second group. Functional variant Val66Met (rs6265) was genotyped from saliva samples by a technician blinded to the identity of DNA samples.ResultsTwenty-seven participants (60.0%) were identified with Val/Val, sixteen (35.5%) with Val/Met genotype, and two with Met/Met genotype. MEP amplitudes were significantly diminished in the Val/Met than Val/Val individuals. These results held independent of the single-pulse TMS paradigm of choice (p = 0.017110% group; p = 0.035 1 mV group), age, and scalp-to-coil distances.ConclusionsThe findings should be further substantiated in larger-scale studies. If validated, intrinsic differences by BDNF polymorphism status could index response to TMS prior to implementing plasticity-inducing protocols.     

Expression of Ciliary Neurotrophic Factor and the Neurotrophins-Nerve Growth Factor,Brain-Derived Neurotrophic Factor and Neurotrophin 3-in Cultured Rat Hippocampal Astrocytes

Cultured astrocytes are known to possess a range of neurotrophic activities in culture. In order to examine which factors may be responsible for these activities, we have examined the expression of the genes for four known neurotrophic factors – ciliary neurotrophic factor (CNTF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) – in purified astrocyte cultures derived from neonatal rat hippocampus. Hippocampal astrocytes were found to express mRNA for three neurotrophic factors – CNTF, NGF and NT3 – at significantly higher levels than other cultured cell types or cell lines examined. BDNF messenger RNA (mRNA), however, was undetectable in these astrocytes. The levels of CNTF, NGF and NT3 mRNA in astrocytes were largely unaffected by their degree of confluency, while serum removal caused only a transient decrease in mRNA levels, which returned to basal levels within 48 h. Astrocyte-derived CNTF was found to comigrate with recombinant rat CNTF at 23 kD on a Western blot. Immunocytochemical analysis revealed strong CNTF immunoreactivity in the cytoplasm of astrocytes, weak staining in the nucleus, but no CNTF at the cell surface. NGF and NT3 were undetectable immunocytochemically. CNTF-like activity, as assessed by bioassay on ciliary ganglion neurons, was found in the extract of cultured astrocytes but not in conditioned medium, whereas astrocyte-conditioned medium supported survival of dorsal root ganglion neurons but not ciliary or nodose ganglion neurons. This conditioned medium activity was neutralized with antibodies to NGF. Astrocyte extract also supported survival of dorsal root ganglion and nodose ganglion neurons, but these activities were not blocked by anti-NGF. Part, but not all, of the activity in astrocyte extracts which sustained nodose ganglion neurons could be attributed to CNTF.